Cardiovascular risk is tough to rule out. The size and length of RIGL trials conducted so far can't rule out cardio risk with increased blood pressure. If R788 works in anti-TNF failure patients, it would change risk/benefit profile for me. If it doesn't, the burden is on them to rule out the cardio risk. Real safety trend won't show up until in larger trial.
Market Data 
Markets 
AI
